Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

On Friday, BIIB stock gained nearly 3%, bringing its trailing-five-day return to more than 5%. In the past month, BIIB has ...

Privately-held dermatology specialist LEO Pharma today revealed robust growth and significantly improved profitability, ...

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

Inside Gilead Sciences, colleagues often describe Varun Sharma as the strategist who can map a launch plan end to end, and ...

H.C. Wainwright analyst Patrick Trucchio assumed coverage of Assembly Biosciences (ASMB) with a Buy rating and $50 price target The firm sees ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

The firm will pick two lead agents targeting PSMA and CLDN18.2 later this year and a third STEAP1-targeting drug next year.

Gilead Sciences ( ($GILD) ) just unveiled an announcement. On August 10, 2025, Gilead Sciences announced the appointment of Erin Burkhart as ...

Legend Biotech announced its Q2 earnings, reporting $439m of revenues for its only commercial product, the cell therapy ...

Key Points Collaboration and license revenue (GAAP) for Q2 2025 was $8.1 million but missed Q2 2025 GAAP revenue estimates by $0.11 million. Net loss (GAAP) widened to $15.8 million, with increased ...